Frequency of anaemia in French cancer patients with solid tumours or haematological diseases. Results from the European Cancer Anaemia Survey (ECAS);Fréquence de l'anémie chez les patients français atteints de tumeurs solides ou d'hémopathies malignes: Résultats de l'«European Cancer Anaemia Survey (EGAS)»

Oncologie

Volumn 7, Issue 5, 2005, Pages 397-402

  Schneider, M ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Anaemia; Chemotherapy; Haematological diseases; Incidence; Prevalence; Radiotherapy; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CORRELATION ANALYSIS; EUROPE; HEALTH SURVEY; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; PERFORMANCE; SOLID TUMOR; STATISTICAL SIGNIFICANCE;

EID: 25144507595     PISSN: 12923818     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10269-005-0247-4     Document Type: Article

References (11)

1. Bray F, Sankila R, Ferlay J, et al. (2002) Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 38: 99-166
2. Caro JJ, Salas M, Ward W, Goss G (2001) Anemia is an independent prognostic factor for survival in patients with cancer. Cancer 91: 2214-21
3. Demetri GD, Kris M, Wade J, et al. (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412-25
4. Fallowfield L, Gagnon D, Zagari M, et al. (2002) Multivariate regression analyses of data from a randomized double-blind, placebo-controlled study confirm quality of life benefit of epoietin alpha in patients receiving non-platinum chemotherapy. Br J Cancer 87 (12): 1341-53
5. Gabrilove J, Cleeland CS, Livingston RB, et al. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875-82
6. Henry DH (2003) Guidelines for the use of epoietin in cancer patients: a much needed step forward in standardizing anemia treatment Blood 2: 2697-8
7. Littlewood TJ, Bajetta E, Nortier JWR, et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-74
8. Ludwig H, Strasser K (2001) Symptomatology of anemia. Sem Oncol 28 (Suppl 2): 7-14
9. Ludwig H, Van Belle S, Barrett-Lee P, et al. (2004) The European Cancer Anaemia Survey (ECAS): A large multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293-3306
10. Osterborg A, Brandberg Y, Molostova V, et al. (2002) Randomized double-blind, placebo-controlled trial of recombinant human erythropoietin beta in hematologic malignancies. J Clin Oncol 20: 2486-94
11. Parkin DM, Bray F, Ferlay J, et al. (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-6